



**PATENT**

Case Docket No. ABGENIX.072A

Date: February 26, 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Landes et al.  
App. No. : 10/726,332  
Filed : December 2, 2003  
For : ANTIBODIES DIRECTED TO  
PHOSPHOLIPASE A2 AND USES  
THEREOF  
Examiner : Not Assigned  
Group Art Unit : Not Assigned

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on

February 26, 2004

(Date)

Michael L. Fuller, Reg. No. 36,516

**TRANSMITTAL LETTER**

**COMMISSIONER FOR PATENTS**


**P.O. Box 1450**


**Alexandria, VA 22313-1450**

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) Information Disclosure Statement in one (1) page.
- (X) Form PTO-1449 listing four (4) references which are also enclosed.
- (X) Return prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

  
Michael L. Fuller  
Registration No. 36,516  
Attorney of Record

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Landes et al.  
App. No. : 10/726,332  
Filed : December 2, 2003  
For : ANTIBODIES DIRECTED TO  
PHOSPHOLIPASE A2 AND USES  
THEREOF  
Examiner : Not Assigned  
Group Art Unit : Not Assigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing four (4) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 26, 2004

By: 

Michael L. Fuller  
Registration No. 36,516  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABGENIX.072A	APPLICATION NO. 10/726,332
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT Landes et al.	
		FILING DATE December 2, 2003	GROUP Not Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1.	Chen et al., "Cloning and Recombinant Expression of a Novel Human Low Molecular Weight Ca <sup>2+</sup> -dependent Phospholipase A <sub>2</sub> ," <i>The Journal of Biological Chemistry</i> , 269: 2365-2368 (1994)
	2.	Cupillard et al., "Cloning, Chromosomal Mapping, and Expression of a Novel Human Secretory Phospholipase A <sub>2</sub> ," <i>The Journal of Biological Chemistry</i> , 272: 15745-15752 (1997)
	3.	Kennedy et al., "A Natural Disruption of the Secretory Group II Phospholipase A <sub>2</sub> Gene in Inbred Mouse Strains," <i>The Journal of Biological Chemistry</i> , 270: 22378-22385 (1995)
	4.	Komada et al., "Structure of Gene Coding for Rat Group II Phospholipase A <sub>2</sub> ," <i>Biochem. Biophys. Res. Commun.</i> , 168: 1059-1065 (1990)

S:\DOCS\SRG\SRG-2579.DOC\022504\vo

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	